Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A survey on low back pain and preventive measures among land freight transportation workers].

Sangyo eiseigaku zasshi = Journal of occupational health·2026
Same author

First-in-human PET study of [<sup>18</sup>F]FSW-100 for imaging histone deacetylase 6 in the brain: safety, biodistribution, radiation dosimetry, and brain kinetic analyses.

Journal of translational medicine·2026
Same author

Effect of Ti Substitution on V-V Dimerization in Ilmenite-Type MgVO<sub>3</sub>.

Inorganic chemistry·2026
Same author

Clinical and MRI features associated with amyloid positivity in secondary screening for anti-amyloid-β therapy.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Mapping of motor and non-motor symptoms to 12-region dopamine transporter single-photon emission computed tomography in Parkinson's disease.

Journal of neurology·2026
Same author

Astrocyte reactivity across the AD continuum measured by [<sup>18</sup>F]SMBT-1 and its relationship with the Aβ burden.

European journal of nuclear medicine and molecular imaging·2026

Related Experiment Video

Updated: Jul 8, 2026

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

[Adenosine receptor--relation to dopaminergic system].

Masahiro Mishina1, Kenji Ishii, Kiichi Ishiwata

  • 1Neurological Institute, Nippon Medical School Chiba Hokusoh Hospital.

Rinsho Shinkeigaku = Clinical Neurology
|January 24, 2008
PubMed
Summary

Adenosine A2A receptors (A2AR) are lower in the affected putamen of Parkinson's disease patients. This finding reveals a new understanding of A2AR and dopamine D2 receptor interactions in early Parkinson's disease.

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Related Experiment Videos

Last Updated: Jul 8, 2026

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Area of Science:

  • Neuroscience
  • Pharmacology
  • Radiochemistry

Context:

  • Adenosine modulates central nervous system synaptic functions.
  • Adenosine A2A receptors (A2AR) are concentrated in dopamine-rich brain regions like the basal ganglia.
  • A2AR are believed to negatively interact with dopamine D2 receptors (D2R).

Purpose:

  • To develop a positron emission tomography (PET) ligand for mapping A2AR in the living human brain.
  • To investigate the relationship between A2AR and early, drug-naive Parkinson's disease (PD).

Summary:

  • A novel PET ligand, [7-methyl-11C]-(E)-8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine ([11C] TMSX), was developed to map A2AR.
  • In normal brains, [11C] TMSX binding potential (BP) was highest in the putamen.
  • In PD patients, [11C] TMSX BP was significantly lower in the more affected putamen, contrasting with D2R upregulation observed in early PD.

Impact:

  • Provides the first in vivo evidence of altered A2AR binding in the human brain in early Parkinson's disease.
  • Suggests an inverse relationship between A2AR and D2R in the pathophysiology of PD.
  • Supports the therapeutic potential of selective A2AR antagonists for Parkinson's disease treatment.